Pharmacogenetics Cardiovascular Panel

Test Code: MPG02
Turnaround time: 10 days
CPT Codes: 81225 x1, 81226 x1, 81227 x1, 81230 x1, 81231 x1, 81355 x1, 81240 x1, 81241 x1

Condition Description

Pharmacogenomics (or pharmacogenetics), abbreviated PGx, is the study of how genes affect a person’s response to certain drugs. PGx testing uses genetic information to predict how individual patients will metabolize some prescription medications. This prediction allows an effective dose to be tailored to a person’s genetic makeup, helping to prevent adverse drug reactions. Pharmacogenetics Cardiovascular Panel targets variants to genotype for various haplotypes among the following 9 genes.

Genes and Alleles Tested:
- **F2**: NM_000506.3:c.*97G>A; rs1799963
- **F5**: NM_000130.4:c.1601G>A(p.R534Q); rs6025
- **SLCO1B1**: *5
- **VKORC1**: NM_024006.4:c.-1639G>A; rs9923231

Note that “*” (read as “star”) denotes the common name of a haplotype (or combination of alleles within a gene on the same chromosome).

Indications

Individuals who meet the defined clinical criteria for being prescribed specific drugs for cardiovascular conditions.

Methodology

The test uses custom manufactured TaqMan® drug metabolism and SNP genotyping assays in 384-well format that are run on the QuantStudio™ 6 Flex platform. The complete test consists of two components: SNP genotyping and copy number quantification. The SNP genotyping component consists of 64 TaqMan® SNP Assays for 63 loci, which include single base and short insertion/deletion polymorphisms. The copy number component consists of one TaqMan® Copy Number assay for the **CYP2D6** gene.

Specimen Requirements

Related Tests

Pharmacogenetics Expanded Panel (MPG01)